Illustrative image.

Brilinta

Name: Brilinta
Brand: Astra Zeneca
Availability: InStock

Ticagrelor

Prescription required

$330.00

60mg · 3 × 56 tablets · 3 months supply

BrandBranded medicine· By Astra Zeneca

$110.00 per month

Strength

How long a supply?

1 month$110.00 a monthOne-off$110.00

3 months$110.00 a monthOne-off$330.00

6 months$110.00 a monthOne-off$660.00

Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$1430a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

60mg

90mg

FDA boxed warningBleeding risk

BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.

Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage

Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) (5.1

6.1).

If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of

subsequent cardiovascular events.

sometimes fatal bleeding.

artery bypass graft surgery (CABG).

Stopping BRILINTA increases the risk of subsequent

cardiovascular events.

Read this with the rest of the clinical information

About Brilinta

Overview

Brilinta (ticagrelor) is a prescription antiplatelet medicine supplied as tablets. It is used to reduce the risk of cardiovascular death, heart attack and stroke in people with acute coronary syndrome or a previous heart attack, and blood clots in stents placed to treat acute coronary syndrome. It also reduces the risk of a first heart attack or stroke in people with high-risk coronary artery disease, and the risk of stroke in people with certain acute ischemic strokes or a high-risk transient ischemic attack (TIA). It works by blocking a signal that activates platelets, helping prevent them from sticking together to form blood clots.

What it treats

- Acute coronary syndrome or a history of heart attack: to reduce the risk of cardiovascular death, heart attack and stroke. - Coronary stent placement for acute coronary syndrome: to reduce the risk of a blood clot in the stent. - Coronary artery disease with a high risk of a first heart attack or stroke: to reduce those risks. - Acute ischemic stroke with a NIH Stroke Scale score of 5 or less, or high-risk transient ischemic attack (TIA): to reduce the risk of stroke.

Safety information

Side effects

The most common side effects are bleeding and shortness of breath. Contact your doctor if you experience either of these side effects.

FDA boxed warning

Bleeding risk

BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.

Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage

Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) (5.1

6.1).

If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of

subsequent cardiovascular events.

sometimes fatal bleeding.

artery bypass graft surgery (CABG).

Stopping BRILINTA increases the risk of subsequent

cardiovascular events.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for heavy or serious bleeding.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Brilinta if you have ever had bleeding inside the skull, have active abnormal bleeding, or are allergic to ticagrelor or any other ingredient in the medicine. Severe liver impairment requires caution because it may increase exposure to ticagrelor. Breastfeeding is not recommended while taking Brilinta. Brilinta may cause shortness of breath, which the label describes as self-limiting. It can also cause false-negative results in platelet function tests used to assess heparin-induced thrombocytopenia (HIT). It is not expected to affect PF4 antibody testing for HIT.

Interactions

Brilinta should not be used with medicines that strongly inhibit or induce CYP3A. Ask your doctor to check whether any of your medicines fall into these groups. Opioids can reduce exposure to ticagrelor; your doctor may consider an injectable antiplatelet medicine. Brilinta can increase the risk of side effects from simvastatin or lovastatin, particularly at higher doses. It may also increase rosuvastatin levels, so monitoring for statin-related side effects is needed. If you take digoxin, its levels should be monitored when Brilinta is started or its treatment is changed.

Using Brilinta

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA PHARMACEUTICALS LP] (DailyMed, retrieved 19 September 2026).

Patient information and references

Official and supporting information to read alongside advice from your prescriber or pharmacist.

Patient information leaflet (PDF)

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.